Published in Gene Therapy Weekly, February 24th, 1997
"We are very pleased with the results, to date, of our collaboration with Introgen," said Thierry Soursac, M.D., Ph.D., RPR Gencell. "In 1997, RPR Gencell is planning to begin two Phase I trials in Europe for both head and neck cancer and hepatocellular cancer and, pending our review of the results of Introgen's ongoing Phase I trials, we plan to conduct a Phase II trial in North America for the treatment of head and neck cancer and possibly other tumor types."
An Investigational New Drug application...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly